DJ MagForce AG: 'NanoTherm School' successfully enters the third round with 'Module B - Part II'
DGAP-Media / 2020-10-20 / 09:50
MagForce AG: _'NanoTherm School'_ successfully enters the third round with
*'Module B - Part II'*
*- *_MagForce successfully hosted the third session of the
practice-oriented, unique and multifaceted application training series for
the use of the NanoTherm therapy system for the treatment of glioblastoma._
_- The NanoTherm School is part of MagForce's commitment to further optimize
the therapy system and train healthcare professionals in its use, and to a
broad geographic coverage to increase the availability of the therapy, in
order to provide glioblastoma patients with the best care possible._
_- The workshop was led by Univ.-Prof. Dr. med. W. Stummer, Director of the
Department of Neurosurgery at the University Hospital Münster_
*Berlin, October 20, 2020* - With _'Module B - Part II - stereotactic
Instillation'_ MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN:
DE000A0HGQF5), a leading medical device company in the field of nanomedicine
focused on oncology, conducted the third round of its _NanoTherm School._
The application training series was launched in January 2019 to provide the
highest quality of treatment through ongoing support for physicians and
certify surgeons in the use of the innovative NanoTherm technology. Same as
the prior two sessions which took place in January and November 2019, Module
B - Part II focused on advanced techniques in the area of stereotactic
instillation and the teaching of the NanoPaste procedure.
Another focus was the exchange of information with the individual treatment
centers to provide the best possible care for glioblastoma patients.
_NanoTherm School_ is part of MagForce's roll-out strategy, which focuses
not only on broad geographical coverage to increase the availability of the
therapy, but also on its continuous further optimization and the training of
healthcare professionals in the use of the therapy system. The training
concept of _NanoTherm School_ was developed in close cooperation with Prof.
Dr. Walter Stummer, Dr. Michael Schwake from the University Hospital Münster
and PD Dr. Johannes Wölfer from the Hufeland Klinikum GmbH Mühlhausen, who
contribute their many years of experience with the NanoTherm therapy system
for the treatment of glioblastoma patients.
Among the workshop participants were also representatives of new clinics
that focus on the treatment of brain tumor patients, such as Dr. Georgios
Naros, M.D., Senior Physician in the Department of Neurosurgery at the
University Hospital of Tübingen and Prof. Dr. Angelika Gutenberg, Head of
the Neurosurgery Section at Asklepios Klinikum Hamburg - her feedback:
"Excellent, hands-on workshop from MagForce. Organization, motivation and
high-end equipment cannot be improved!"
Senior Physician MUDr. Vilem Ruzicka, Paracelsus Klinik Zwickau said: "Thank
you for a super organized certification course at the NanoTherm Therapy
School of MagForce. It was a very successful and, above all, instructive
workshop that provides us as medical practitioners with excellent training
in the application of new technologies and therapies. This applies in
particular to the very practical training of the various instillation
methods and the subsequent evaluation of the results. The preparation and
execution were very good, and overall it must be said that the set-up in the
'Medicine in the Green' is excellently suited for such workshops."
About _NanoTherm School_
Targeted towards medical professionals working in the fields of
neuro-surgery and neuro-oncology, the '_NanoTherm Therapy School'_ series
aims at introducing participants to the theoretical knowledge and practical
techniques required to successfully apply MagForce's NanoTherm technology
for the treatment of glioblastoma. In practicing their skills with human
specimens, participants are able to familiarize themselves with the
procedures and device usages in a stress-free environment under largely real
operating conditions.
The '_NanoTherm School'_ is designed in three consecutive modules allowing
participants to gain knowledge and understanding of MagForce's NanoTherm
technology starting from basic application techniques (nanopasting) and
building to advanced techniques and new surgical application forms in the
final module (Module C). The practical section of the course is complemented
by lectures on directly relevant aspects of NanoTherm therapy, as well as
sample preparation and surgical videos. The equipment and facilities used
during the course meet the requirements of today's state-of-the-art surgical
equipment.
*For more information about NanoTherm School, please contact:*
Dipl.-Ing. Tobias Hanitsch (thanitsch@magforce.com) Marcel Pilz
(mpilz@magforce.com)
_About MagForce AG and MagForce USA, Inc._
_MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm therapy system enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. _
_NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices for
the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and
NanoActivator are trademarks of MagForce AG in selected countries. _
*For more information, please visit: www.magforce.com [1].
Get to know our Technology: video (You Tube) [2]
Stay informed and subscribe to our mailing list [3]*
*Disclaimer *
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
Contact:
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com
End of Media Release
Issuer: MagForce AG
Key word(s): Health
2020-10-20 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt
(Scale), Stuttgart, Tradegate Exchange
EQS News ID: 1141804
End of News DGAP Media
1141804 2020-10-20
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8c9fb96f72ca3bbe10dd7f041cbe6fa6&application_id=1141804&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=fee20ce56f7c48d1562a60533ead43c9&application_id=1141804&site_id=vwd&application_name=news
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f35fad65a8bc4664a072c1fef1651402&application_id=1141804&site_id=vwd&application_name=news
(END) Dow Jones Newswires
October 20, 2020 03:50 ET (07:50 GMT)
